Nancy M. Holekamp, MD - Eyeing the Benefits and Risks of VEGF-Targeted Therapies for nAMD

CME in Minutes: Education in Primary Care

EpisodeAug 31, 202214m

Nancy M. Holekamp, MD - Eyeing the Benefits and Risks of VEGF-Targeted Therapies for nAMD

CME in Minutes: Education in Primary Care

EpisodeAug 31, 202214m

Please visit answersincme.com/BJH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in retinal disease discusses strategies for treating patients with intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Describe management strategies to optimize outcomes for patients receiving intravitreal VEGF-targeted therapy for nAMD.

Top comments

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Primary Care by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for the busy primary care providers to cover the diagnosis, treatment, follow-up, and clinical management of various disease states. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

answersincme.com

Switch to the Fountain App

Open in Fountain